VA
CTMX icon

Verdad Advisers’s CytomX Therapeutics CTMX Stock Holding History

Verdad Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$662K Buy
176,407
+146,220
+484% +$558K 0.63% 52
2026
Q1 		$142K Buy
+30,187
New +$153K 0.16% 142

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Verdad Advisers's CTMX Position: Q2 2026 in Review

Verdad Advisers increased its CytomX Therapeutics (CTMX) stake by 484% in Q2 2026, buying an estimated $558K and bringing the position to 176,407 shares worth $662K. The position accounts for 0.63% of the portfolio, ranked #52.

Verdad Advisers first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Verdad Advisers held 176,407 shares of CytomX Therapeutics worth $662K as of Q2 2026.
  • Verdad Advisers bought 146,220 CytomX Therapeutics shares in Q2 2026, an estimated $558K.
  • CytomX Therapeutics made up 0.63% of Verdad Advisers's portfolio in Q2 2026, its #52 holding.
  • Verdad Advisers first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.